ANALYSIS OF IN VIVO HPRT MUTATIONS IN PREMATURE INFANTS
早产儿体内 HPRT 突变分析
基本信息
- 批准号:6277158
- 负责人:
- 金额:$ 2.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-12-01 至 1998-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Spontaneous somatic mutant frequencies and mutational spectra at the
hypoxanthine - guanine phosphoribosyl transferase (hprt) locus in human T-
lymphocytes show a strict age dependency from birth to adults (Mut. Res.
1994). To date, no studies have evaluated spontaneous somatic mutant
frequencies (MF) in preterm infants. We determined the MF at the hprt
locus in preterm infants between 26 and 36 weeks gestation at the time of
delivery. A maternal questionnaire, review of the maternal medical record,
and determination of plasma cotinine levels were also conducted. History
of passive/active cigarette smoke exposure during pregnancy, exposure to
medications, and exposure to excessive radiation were evaluated during
pregnancy and compared to MF. Infants with known genetic syndromes, major
systemic illness or major congenital anomalies were excluded. The cloning
efficiency and MF were determined using the hprt T-cell cloning assay, the
most widely used assay for determining the frequency and mutational
spectra of spontaneous and genotoxic induced somatic genetic mutations in
humans. Cord blood samples were obtained from 48 infants, of which 25 were
included in the MF analysis. Reasons for non-inclusion were clotted blood
(4), insufficient number of cells (6), and no identifiable mutants (13).
MF data was obtained from subjects with a mean gestational age of 31.8
weeks. No significant radiation exposure or exposure to genotoxic
medications were reported. Medication exposure during pregnancy consisted
of, terbutaline, magnesium sulfate, and betamethasone. There were 4
mothers with a history of active/passive cigarette smoke exposure based on
questionnaire data. The mean MF for all subjects was 3.44 x l0-6 + 0.44 x
l0-6 which is significantly higher than the mean MF in term infants, 1.18
x 10-6 + 0.07 x 10-6. The elevation in mean MF in preterm infants does not
appear to be the result of maternal exposures. The MF data obtained
demonstrates premature infants have a higher MF than term infants. The
elevation in MF may reflect an increase in mutations in rapidly dividing
lymphoid cells that subsequently undergo apoptosis prior to 38 weeks
gestation. These observations suggest that lymphoid cells in the
developing fetus may be at a higher risk of obtaining somatic mutations
spontaneously or as a result of genotoxic exposure.
自发体细胞突变频率和突变谱
人 T- 中的次黄嘌呤 - 鸟嘌呤磷酸核糖转移酶 (hprt) 位点
淋巴细胞从出生到成年表现出严格的年龄依赖性(Mut. Res.
1994)。迄今为止,还没有研究评估自发体细胞突变
早产儿的频率(MF)。我们确定了 hprt 处的 MF
妊娠 26 至 36 周之间的早产儿的位点
送货。产妇调查问卷、产妇病历审查、
还进行了血浆可替宁水平的测定。历史
怀孕期间被动/主动接触香烟烟雾、接触
期间对药物治疗和过度辐射暴露进行了评估
怀孕并与 MF 相比。患有已知遗传综合征的婴儿,主要
排除全身性疾病或重大先天异常。克隆
使用 hprt T 细胞克隆测定法测定效率和 MF,
用于确定频率和突变的最广泛使用的测定法
自发和遗传毒性诱导的体细胞基因突变谱
人类。采集了 48 名婴儿的脐带血样本,其中 25 名是
包含在 MF 分析中。未纳入的原因是凝血
(4),细胞数量不足(6),并且没有可识别的突变体(13)。
MF 数据取自平均孕龄为 31.8 岁的受试者
几周。没有明显的辐射暴露或遗传毒性暴露
报告了药物治疗。怀孕期间的药物暴露包括
特布他林、硫酸镁和倍他米松。有 4 个
有主动/被动吸烟史的母亲基于
问卷数据。所有受试者的平均 MF 为 3.44 x l0-6 + 0.44 x
l0-6 显着高于足月儿的平均 MF 1.18
x 10-6 + 0.07 x 10-6。早产儿平均 MF 的升高并不
似乎是母亲接触的结果。 获得的MF数据
表明早产儿的 MF 高于足月儿。这
MF 的升高可能反映了快速分裂中突变的增加
随后在 38 周之前发生凋亡的淋巴细胞
妊娠。 这些观察结果表明,淋巴样细胞
发育中的胎儿获得体细胞突变的风险可能更高
自发地或由于遗传毒性暴露而发生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT A SILVER其他文献
ROBERT A SILVER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT A SILVER', 18)}}的其他基金
ANALYSIS OF IN VIVO HPRT MUTATIONS IN PREMATURE INFANTS
早产儿体内 HPRT 突变分析
- 批准号:
6247014 - 财政年份:1997
- 资助金额:
$ 2.62万 - 项目类别:
相似海外基金
Greatwall in replication stress/DNA damage responses and oral cancer resistance
长城在复制应激/DNA损伤反应和口腔癌抵抗中的作用
- 批准号:
10991546 - 财政年份:2024
- 资助金额:
$ 2.62万 - 项目类别:
The shielding role of the nuclear periphery against the genetic and non-genetic consequences of DNA damage (ChromoSENSOR)
核外围对 DNA 损伤的遗传和非遗传后果的屏蔽作用 (ChromoSENSOR)
- 批准号:
EP/Y027124/1 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Research Grant
Aspartate beta-hydroxylase and DNA damage in chronic liver diseases
慢性肝病中的天冬氨酸 β-羟化酶和 DNA 损伤
- 批准号:
10667881 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Role of DNA damage and cellular senescence in osteoarthritis pathophysiology
DNA 损伤和细胞衰老在骨关节炎病理生理学中的作用
- 批准号:
10801026 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Impact of ATR's role in translesion synthesis on prevention of DNA damage induced mutagenesis and chromosomal instability
ATR 在跨损伤合成中的作用对预防 DNA 损伤诱导的突变和染色体不稳定性的影响
- 批准号:
10634852 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factor
转录、DNA 损伤和表观遗传学的界面:EWS-FLI1 转录因子的治疗脆弱性
- 批准号:
10718793 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Investigating metabolism and DNA damage repair in uropathogenic Escherichia coli fluoroquinolone persisters
研究泌尿道致病性大肠杆菌氟喹诺酮类持续存在的代谢和 DNA 损伤修复
- 批准号:
10747651 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Targeting the function of BRCA1 in the DNA damage response network.
靶向 DNA 损伤反应网络中 BRCA1 的功能。
- 批准号:
2879783 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Studentship
Elucidation of the mechanism underlying cellular senescence and aging induced by the continuous DNA damage
阐明持续DNA损伤引起的细胞衰老和老化的机制
- 批准号:
22KJ0646 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
TAZ 和 YAP 在 3D 基因组组织 DNA 损伤修复中的新作用以及胶质母细胞瘤的治疗耐药性
- 批准号:
10649830 - 财政年份:2023
- 资助金额:
$ 2.62万 - 项目类别:














{{item.name}}会员




